Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 0.84
ARIA's Cash to Debt is ranked higher than
55% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ARIA: 0.84 )
ARIA' s 10-Year Cash to Debt Range
Min: 0.8   Max: 24.17
Current: 0.84

0.8
24.17
Equity to Asset 0.17
ARIA's Equity to Asset is ranked higher than
53% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ARIA: 0.17 )
ARIA' s 10-Year Equity to Asset Range
Min: -2.2   Max: 0.89
Current: 0.17

-2.2
0.89
F-Score: 2
Z-Score: -2.56
M-Score: -3.17
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -483.41
ARIA's Operating margin (%) is ranked higher than
61% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. ARIA: -483.41 )
ARIA' s 10-Year Operating margin (%) Range
Min: -526300   Max: 58.61
Current: -483.41

-526300
58.61
Net-margin (%) -492.24
ARIA's Net-margin (%) is ranked higher than
61% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. ARIA: -492.24 )
ARIA' s 10-Year Net-margin (%) Range
Min: -493975   Max: 194.03
Current: -492.24

-493975
194.03
ROE (%) -146.51
ARIA's ROE (%) is ranked higher than
55% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. ARIA: -146.51 )
ARIA' s 10-Year ROE (%) Range
Min: -523.41   Max: 93.23
Current: -146.51

-523.41
93.23
ROA (%) -55.01
ARIA's ROA (%) is ranked higher than
62% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. ARIA: -55.01 )
ARIA' s 10-Year ROA (%) Range
Min: -120.13   Max: 92.14
Current: -55.01

-120.13
92.14
ROC (Joel Greenblatt) (%) -175.74
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
78% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. ARIA: -175.74 )
ARIA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2869.58   Max: 1329.95
Current: -175.74

-2869.58
1329.95
Revenue Growth (%) -45.70
ARIA's Revenue Growth (%) is ranked higher than
61% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. ARIA: -45.70 )
ARIA' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 214.8
Current: -45.7

0
214.8
» ARIA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ARIA Guru Trades in Q4 2013

Chuck Royce 686,602 sh (New)
George Soros 1,950,000 sh (New)
Paul Tudor Jones 18,432 sh (New)
Steven Cohen 93,800 sh (+66.96%)
Louis Moore Bacon Sold Out
Manning & Napier Advisors, Inc Sold Out
Columbia Wanger Sold Out
» More
Q1 2014

ARIA Guru Trades in Q1 2014

Jim Simons 2,248,846 sh (New)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Chuck Royce 516,602 sh (-24.76%)
George Soros 500,000 sh (-74.36%)
» More
Q2 2014

ARIA Guru Trades in Q2 2014

George Soros 1,000,000 sh (+100%)
Jim Simons 4,399,981 sh (+95.66%)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 480,602 sh (-6.97%)
» More
Q3 2014

ARIA Guru Trades in Q3 2014

Stanley Druckenmiller 1,645,000 sh (New)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 440,602 sh (-8.32%)
Jim Simons 1,252,681 sh (-71.53%)
George Soros 150,000 sh (-85%)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-09-30 Reduce -85%0.04%$5.01 - $6.5 $ 6.6113%150000
George Soros 2014-06-30 Add 100%0.02%$6.3 - $8.52 $ 6.61-4%1000000
George Soros 2014-03-31 Reduce -74.36%0.08%$6.46 - $8.99 $ 6.61-15%500000
George Soros 2013-12-31 New Buy0.11%$2.2 - $18.8 $ 6.6128%1950000
Daniel Loeb 2013-06-30 Sold Out 0.94%$16.32 - $19.77 $ 6.61-63%0
Daniel Loeb 2012-12-31 Add 85.19%0.4%$18.93 - $25.16 $ 6.61-70%2500000
Andreas Halvorsen 2012-12-31 Sold Out 0.33%$18.93 - $25.16 $ 6.61-70%0
Daniel Loeb 2012-09-30 Reduce -35.71%0.39%$17.11 - $24.21 $ 6.61-67%1350000
Andreas Halvorsen 2012-09-30 New Buy0.33%$17.11 - $24.21 $ 6.61-67%1934500
Daniel Loeb 2012-06-30 New Buy1.1%$14.6 - $17.82 $ 6.61-60%2100000
George Soros 2012-06-30 Sold Out 0.15%$14.6 - $17.82 $ 6.61-60%0
George Soros 2012-03-31 New Buy0.15%$12.73 - $16.32 $ 6.61-52%635000
George Soros 2011-12-31 Sold Out 0.07%$8.03 - $12.5 $ 6.61-40%0
George Soros 2011-09-30 New Buy0.07%$7.63 - $13.34 $ 6.61-37%496847
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 15.37
ARIA's P/B is ranked higher than
62% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. ARIA: 15.37 )
ARIA' s 10-Year P/B Range
Min: 1.69   Max: 222.33
Current: 15.37

1.69
222.33
P/S 26.26
ARIA's P/S is ranked higher than
74% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. ARIA: 26.26 )
ARIA' s 10-Year P/S Range
Min: 1.71   Max: 1334
Current: 26.26

1.71
1334
EV-to-EBIT -5.67
ARIA's EV-to-EBIT is ranked higher than
54% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ARIA: -5.67 )
ARIA' s 10-Year EV-to-EBIT Range
Min: -31.7   Max: 10.4
Current: -5.67

-31.7
10.4
Current Ratio 3.97
ARIA's Current Ratio is ranked higher than
70% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. ARIA: 3.97 )
ARIA' s 10-Year Current Ratio Range
Min: 0.62   Max: 15.1
Current: 3.97

0.62
15.1
Quick Ratio 3.96
ARIA's Quick Ratio is ranked higher than
71% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ARIA: 3.96 )
ARIA' s 10-Year Quick Ratio Range
Min: 0.52   Max: 14.95
Current: 3.96

0.52
14.95

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 15.37
ARIA's Price/Tangible Book is ranked higher than
67% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. ARIA: 15.37 )
ARIA' s 10-Year Price/Tangible Book Range
Min: 0.86   Max: 1133
Current: 15.37

0.86
1133
Price/Median PS Value 0.34
ARIA's Price/Median PS Value is ranked higher than
96% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ARIA: 0.34 )
ARIA' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 13.99
Current: 0.34

0.01
13.99
Earnings Yield (Greenblatt) -17.60
ARIA's Earnings Yield (Greenblatt) is ranked higher than
60% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. ARIA: -17.60 )
ARIA' s 10-Year Earnings Yield (Greenblatt) Range
Min: 9.6   Max: 42.7
Current: -17.6

9.6
42.7

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:APS.Germany, ARIA.Switzerland,
Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
» More Articles for ARIA

Headlines

Articles On GuruFocus.com
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 15 2013 
comment on ARIA Mar 15 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
creiter note on ARIA Jan 03 2010 

More From Other Websites
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 11 2014
Mid-Morning Market Update: Markets Surge; Lululemon Profit Beats Expectations Dec 11 2014
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action? Dec 11 2014
Analysts' Actions: AbbVie, Ariad, Lilly, Prologis, Toll Brothers Dec 11 2014
UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak Dec 11 2014
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid... Dec 09 2014
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid... Dec 09 2014
ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I... Dec 09 2014
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Dec 08 2014
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial Dec 08 2014
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% Nov 25 2014
ARIAD Pharmaceuticals (ARIA) Strong On High Relative Volume Today Nov 24 2014
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia Nov 24 2014
ARIAD and STA Announce Approval of Iclusig (Ponatinib) in Australia Nov 24 2014
ARIAD PHARMACEUTICALS INC Financials Nov 14 2014
Stalking an Entry Into Ariad Pharmaceutical Nov 12 2014
10-Q for ARIAD Pharmaceuticals, Inc. Nov 09 2014
ARIAD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting Nov 06 2014
ARIAD Announces Iclusig Data Presentations at Annual American Society of Hematology Meeting Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK